Business Context and Reporting Period
This Form 8-K Current Report was filed by Black Diamond Therapeutics, Inc. on December 13, 2023. The filing discloses topline results from the dose escalation portion of a Phase 1 clinical trial for the investigational drug BDTX-1535 in patients with recurrent glioblastoma (GBM).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial data and does not contain financial statements.
Material Changes and Clinical Results
The primary material event is the announcement of clinical data as of November 2023 regarding 27 patients with recurrent GBM treated with BDTX-1535.
- Safety Profile: No new safety signals were observed. Adverse events were consistent with the EGFR tyrosine kinase inhibitor class, primarily Grade 1 and 2 diarrhea and rash.
- Efficacy in GBM: Of 22 evaluable patients (dosed at 100 mg QD or greater), one patient achieved a confirmed partial response, and eight experienced stable disease.
- Durability: Three patients remained on therapy longer than ten months, one longer than six months, and five longer than four months. This contrasts with historical progression-free survival in this population, which ranges from two to four months.
- Notable Case: One patient has been on BDTX-1535 at 100 mg QD for over fifteen months with prolonged disease stabilization after progressing on temozolomide.
- Cross-Indication Data: Patients with non-small cell lung cancer dosed at 100 mg QD or greater demonstrated confirmed partial responses in lung lesions and central nervous system metastases.
Guidance, Outlook, and Risks
The Company plans to submit results from the dose escalation GBM cohort for presentation at a medical meeting in the second quarter of 2024. Management commentary highlights the potential for BDTX-1535 to benefit patients in an earlier line of treatment.
The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially due to risks associated with clinical development, regulatory approval, and the uncertain nature of drug advancement. Specific risks are referenced in the Company's Annual Report on Form 10-K for the year ended December 31, 2022.
Investor Verification Checklist
- Verify the full clinical data presentation scheduled for Q2 2024 to confirm the durability of the reported responses.
- Review the Company's most recent Form 10-K or 10-Q for current cash runway and liquidity status, as this 8-K contains no financial data.
- Confirm the specific EGFR alteration status of the patients who responded, noting that EGFR status was not known at the time of treatment for most patients.
- Monitor upcoming regulatory filings for any updates on the Phase 1 trial design or expansion cohorts.